The directors of Asarina Pharma have finally found a buyer for the Tourette’s syndrome treatment sepranolone after securing a bittersweet deal with US firm Relmada Therapeutics which comes four months
The news that Asarina Pharma is going into liquidation is a disappointment both to the Swedish biotech's shareholders and to Tourette's syndrome patients hoping for safer and more effective therapie
Biopharma Financing Biopharma financings during the fourth quarter of 2022 totaled $17.5bn from 282 deals; of those, 53 financings met or exceeded the $100m mark. Overall, follow on public offerings (
Tourette's syndrome has proved a tough nut to crack pharmacologically but a couple of biotechs – Sweden's Asarina Pharma and Emalex Biosciences Inc. in the US – are advancing promising candidates